Eli Lilly
Eli Lilly Acquires Scorpion Therapeutics for Up to $2.5 Billion to Bolster Oncology Pipeline
Eli Lilly, Scorpion Therapeutics, PI3Kα inhibitor, STX-478, cancer treatment, oncology pipeline, acquisition, biotech deal
Eli Lilly Acquires Scorpion Therapeutics in $2.5 Billion Deal to Boost Breast Cancer Treatment Options
Eli Lilly, Scorpion Therapeutics, breast cancer, PI3Kα inhibitor, STX-478, oncology pipeline, targeted therapy
Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal
Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.
Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies
Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development
Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies
Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry
Eli Lilly Seeks to Intervene in FDA Lawsuit Over Compounded Tirzepatide to Safeguard Interests
Eli Lilly, FDA lawsuit, compounded tirzepatide, weight loss drugs, pharmaceutical industry, regulatory issues
Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution
Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound
FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders
FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound
Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment
Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy
Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase
Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market